Eli Lilly & Co.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $20.64B | $10.59B | $5.24B | $6.24B | $5.58B | $6.19B | $8.32B | $3.23B |
| Depreciation & Amortization | $2.00B | $1.77B | $1.53B | $1.52B | $1.55B | $1.32B | $1.23B | $1.61B |
| Depreciation | $1.31B | $1.06B | $902.0M | $816.6M | $787.0M | $765.2M | $814.7M | $797.1M |
| Amortization | $488.0M | $553.0M | $506.0M | $579.7M | $628.8M | $428.2M | $225.8M | $361.3M |
| Stock-Based Compensation | $626.0M | $646.0M | $629.0M | $371.1M | $342.8M | $308.1M | $312.4M | $279.5M |
| Net Cash from Operating Activities | $16.81B | $8.82B | $4.24B | $7.59B | $7.37B | $6.50B | $4.84B | $5.52B |
| Investing Activities | ||||||||
| Capital Expenditures | $7.84B | $5.06B | $3.45B | $1.85B | $1.31B | $1.39B | $1.03B | $1.21B |
| Business Acquisitions | — | — | — | $327.2M | $747.4M | $849.3M | $6.92B | $0 |
| Net Cash from Investing Activities | $-10.97B | $-9.30B | $-7.15B | $-3.76B | $-2.87B | $-2.26B | $-8.08B | $1.91B |
| Financing Activities | ||||||||
| Dividends Paid | $5.38B | $4.68B | $4.07B | $3.54B | $3.09B | $2.69B | $2.41B | $2.31B |
| Stock Repurchases | $4.11B | $2.50B | $750.0M | $1.50B | $1.25B | $500.0M | $4.40B | $4.15B |
| Net Cash from Financing Activities | $-2.21B | $1.23B | $3.50B | $-5.41B | $-4.13B | $-3.14B | $-2.32B | $-5.90B |
| Net Change in Cash | $4.00B | $449.0M | $752.0M | $-1.75B | $161.4M | $1.32B | $-5.66B | $1.46B |
| Free Cash Flow | $8.97B | $3.76B | $792.0M | $5.73B | $6.06B | $5.11B | $3.80B | $4.31B |